SEATTLE, July 03, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering Pascal Biosciences Inc. (TSX-V:PAS), a drug discovery and development company focused on harnessing the body’s immune system to fight cancer. The company made an important discovery earlier this year that could impact the multi-billion dollar checkpoint inhibitor class of drugs.
Cannabinoids have been widely used in oncology for nausea, appetite stimulation, and pain reduction in patients undergoing chemotherapy, but some researchers believe that they could play a more active role in combating the disease. While cannabis hasn’t been shown to cure cancer on its own, despite the pervasiveness of anecdotal stories, scientists have found that cannabinoids have anti-cancer properties that could be helpful in drug development.
Pascal’s Immunotherapy Breakthrough
Most tumor cells are recognized by the immune system and destroyed through a process called immunosurveillance, but some malignant cells (e.g. metastatic cells) employ an immune escape strategy to subvert these processes. By avoiding detection by the immune system, these cells spread to other tissues and eventually lead to fatal cancers.
A new branch of cancer research has emerged, called immunotherapy, that’s focused on helping the immune system recognize and destroy cancerous cells. In particular, checkpoint inhibitors are a class of immunotherapy drugs designed to activate the immune system to destroy cancer cells. Commercial checkpoint inhibitors, like Opdivo®, Keytruda®, and Yervoy®, have been shown to greatly improve survival in many cancer patients and combined had over $6 billion in 2017 sales.
Pascal Biosciences announced earlier this year the discovery of certain cannabinoids that enhance the immunogenicity of tumor cells. Dr. Wilfred Jefferies, the Scientific Founder of Pascal Biosciences, and professor at the University of British Columbia, and his team screened thousands of natural products using a proprietary assay focused on discovering compounds that can increase immune recognition of tumor cells. By making these cancerous cells more susceptible to recognition by the immune system, these cannabinoids could play an important role in augmenting the activity of checkpoint inhibitors that activate the immune system to defeat cancer.
“We are very excited by this novel discovery,” said Pascal Biosciences CEO Dr. Patrick Gray. “Cannabinoids typically have good pharmacological properties, as most have low toxicity and are easily absorbed into the blood, which are great advantages for drug development. In combination with immune checkpoint inhibitors, cannabinoids may significantly improve cancer care. We look forward to soon translating our results into clinical studies.”
Moving Toward Clinical Trials
Pascal Biosciences has been making steady progress towards moving these discoveries towards clinical trials.
On June 18, the company announced that it secured a license from the U.S. Drug Enforcement Administration to conduct research and development on cannabinoids. Health Canada also granted Dr. Jefferies’ laboratory, at the Michael Smith Laboratories, an exemption under the Controlled Drugs and Substances Act for the research. Both licenses enable the company to immediately conduct advanced research and development on cannabinoids.
The company also renewed its collaboration with the University of British Columbia, which provided the proprietary assay that contributed to the discovery, and continued its financial support of Dr. Jeffries’ laboratory at the Michael Smith Laboratories. “Together we have made great progress in developing a cannabinoid for cancer,” said Dr. Jefferies. “Pascal’s continued financial support will help enable a lead product to complete preclinical efforts for treatment of patients with cancer.”
Pascal Biosciences Inc. (TSX-V:PAS) represents a unique investment opportunity following its novel discovery of cannabinoids that could help identify tumor cells. With checkpoint inhibitors already generating billions of dollars per year successfully advancing cancer treatments, these cannabinoids could prove to be extremely valuable if they help expand the potential market for checkpoint inhibitors and help a wider patient population.
For more information, visit the company’s website at www.pascalbiosciences.com.
Please follow the link to read the full article: http://www.cannabisfn.com/pascal-biosciences-cannabinoids-play-role-destroying-cancer-cells/
About CFN Media
CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany
Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com
CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/